Table 2.

Adverse events (AEs) with frequencies >1%; absolute number and percentage of G3-G4 for each event pre- and post-switch.

Adverse event (N=200)		Before switch					After switch				P	Only after switch
		Patients with AE		G3-G4 grading			Patients with AE		G3-G4 grading
		N	%	N	%		N	%	N	%		N	%
21	Muscular cramps	77	38.5	1	1.3		42	21.0	2	4.8	<0.0001	14	7.0
20	Edema limbs	41	20.5	3	7.3		17	8.5	0	0.0	<0.0001	2	1.0
19	Diarrhea	38	19.0	1	2.6		20	10.0	2	10.0	0.0027	9	4.5
18	Periorbital edema	35	17.5	0	0.0		21	10.5	0	0.0	0.0028	4	2.0
17	Fatigue	33	16.5	1	3.0		22	11.0	1	4.5	0.0482	10	5.0
16	Arthralgia	22	11.0	0	0.0		21	10.5	0	0.0	0.8575	15	7.5
15	Cutaneous rash	18	9.0	0	0.0		6	3.0	0	0.0	0.0027	2	1.0
14	Myalgia	16	8.0	1	6.3		4	2.0	0	0.0	0.0027	2	1.0
13	Nausea	12	6.0	1	8.3		9	4.5	1	11.1	0.4669	7	3.5
12	Conjunctival hyperemia	12	6.0	1	8.3		7	3.5	0	0.0	0.2253	6	3.0
11	Creatinine increased	7	3.5	0	0.0		2	1.0	0	0.0	0.6547	2	1.0
10	Other skin and subcutaneous tissue disorders	7	3.5	1	14.3		6	3.0	1	16.7	0.0588	1	0.5
9	Dyspepsia	6	3.0	1	16.7		1	0.5	0	0.0	0.3173	3	1.5
8	Anemia	6	3.0	0	0.0		3	1.5	0	0.0	0.0588	1	0.5
7	Headache	5	2.5	0	0.0		4	2.0	2	50.0	0.7055	3	1.5
6	Increased transaminase levels	4	2.0	0	0.0		0	0.0	0	0.0	0.0455	0	0.0
5	Neutrophil count decreased	4	2.0	2	50.0		0	0.0	0	0.0	0.0455	0	0.0
4	Blurred vision	3	1.5	0	0.0		1	0.5	0	0.0	1.0000	1	0.5
3	Hypertension	3	1.5	0	0.0		3	1.5	0	0.0	0.1573	0	0.0
2	Paresthesia	3	1.5	0	0.0		1	0.5	0	0.0	0.3173	1	0.5
1	Lipase increased	1	0.5	0	0.0		3	1.5	0	0.0	0.1573	2	1.0